BeiGene shareholders approve equity plan share increases and director re-elections at AGM

BeOne Medicines Ltd.

Approved Third Amended 2016 Share Option Plan, adding 92.82M shares to the reserve.
Approved Fourth Amended 2018 ESPP, increasing share availability by 5.07M shares.
Re-elected Class II directors Brandicourt, Glazer, Goller, Sanders with strong support.
Approved general mandates to issue up to 20% and repurchase up to 10% of shares.
Approved RSUs and PSUs to CEO John Oyler ($6M each) and other executive grants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.